Follow The Filings

IPSC Century Therapeutics

Century Therapeutics earnings company data as of 4:48 AM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 12 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by IPSC's executives, directors and 10% owners in the last 12 months, from their Form 4s

All IPSC insider trades
  • $97K bought by 2 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Chad Cowan Chief Scientific Officer
    Buy
    $49K 58,060 shares at $0.8500 +5.9% to stake
    Traded Dec 22, 2025 Filed Dec 29, 2025
  2. Brent Pfeiffenberger CEO
    Buy
    $30K 52,000 shares at $0.5800 +1.6% to stake
    Traded Dec 12, 2025 Filed Dec 16, 2025
  3. Brent Pfeiffenberger CEO
    Buy
    $17K 35,000 shares at $0.5000 +1.1% to stake
    Traded Nov 19, 2025 Filed Nov 20, 2025

Also filed in the last 12 months, not counted as buying or selling: 20 sales to cover taxes, 14 share withholdings for taxes, and 4 stock grants.

SEC filings

Recent issuer filings from EDGAR, 15 shown.

Filed Form Detail Links
8-K 7.01,8.01,9.01
8-K 5.02,7.01,9.01
10-Q
8-K 2.02,7.01,9.01
8-K 5.02
8-K 5.03,5.07,9.01
8-K 8.01,9.01
424B7
SCHEDULE 13G —
SCHEDULE 13G/A —
10-Q
8-K 2.02,9.01
DEF 14A FORM DEF 14A
DEFA14A
8-K 8.01,9.01

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.